Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Acute Respiratory Distress Syndrome Market $16.9 Billion by 2027

The global market for acute respiratory distress syndrome devices anticipated to attain $16.9 billion by 2027, expanding at a CAGR of 7.2% over the forecast period, driven by increasing prevalence and incidence of acute lung injury and associated clinical conditions, rising aging population and lack of pharmacological treatments.

Global Acute Respiratory Distress Syndrome Devices Market

Acute lung injury (ALI) and its more severe form acute respiratory distress syndrome (ARDS) are clinical syndromes of acute respiratory failure is associated with substantial morbidity and mortality.

  • Acute respiratory distress syndrome is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs or acute lung injury.
    • ARDS is an acute and severe lung injury leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening due to respiratory failure and/or multi-organ dysfunction.

There is an unmet medical need, as the syndrome of acute respiratory failure is very common both in the United States and worldwide. Other factors such as age and associated clinical disorders may impact the incidence of ALI and ARDS.

  • Predisposing clinical factors include sepsis, pneumonia, aspiration, trauma, pancreatitis, blood transfusions, and smoke or toxic gas inhalation.
    • Severe sepsis and multiple transfusions are associated with the highest incidence of ARDS; the lowest rates occur in patients with trauma or drug overdoses.
      • For patients with multiple comorbidities, chronic alcohol abuse, or chronic lung disease, the risk for lung injury is higher.

Globally, ARDS affects more than 3 million people a year accounting for 10% of intensive care unit admissions, and approximately 200 000 patients each year in the United States.

  • The incidence of ALI is reported as 17-34 per 100,000 person years.
    • Unfortunately, despite population studies, the incidence of ALI/ARDS has been difficult to assess due to nonuniform definitions, etiologic variations, geographical variation, inadequate documentation, and under recognition of disease entity.

There are no effective pharmacological therapies specifically approved for ARDS.

  • The treatment is supportive with lung-protective mechanical ventilation, where primary treatment involves nonpharmacological approaches such as mechanical ventilation and oxygen supplementation treatments directed at the underlying cause.
    • The delivery of potential therapies via aerosol to the distal air spaces of the lung remains a viable delivery route for both small molecules and proteins. Depending on the treatment modality, aerosol delivery may avoid systemic effects and more specifically target the lung.

The global acute respiratory distress syndrome products market research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).

The global market for acute respiratory distress syndrome segmented by product [airway and pulmonary management devices (anesthesia and respiratory masks, pulmonary function diagnostic devices – spirometry, others; ventilators – positive airway pressure devices, others; other devices; drug/fluid delivery and infusion therapy devices (inhalation devices – nebulizers)], end users (hospitals, clinics, others) and geography.

  • Based on products, the airway and pulmonary management devices segment accounted for the largest share of the total market.
    • The positive airway pressure devices sub-segment representing ventilators segment dominated the overall acute respiratory distress syndrome market, and is expected to grow at the fastest rate during the coming years.
      • The main supportive therapy for ARDS is positive pressure mechanical ventilation involving low tidal volume ventilation/protective ventilation which helps to ensure adequate oxygenation.
  • The spirometry devices sub-segment anticipated to register higher CAGR than nebulizers sub-segment during the forecast period.

The global acute respiratory distress syndrome devices market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Geographically, the North America and Europe regions dominated the global ARDS devices market.
    • The higher market share attributed to increasing incidence of acute lung injuries leading to acute respiratory distress syndrome, high cost of products, presence of sophisticated healthcare infrastructure, and favorable reimbursement policies in the developing countries.
  • However, the Asia Pacific region and other emerging countries predicted to account for considerable share of the global market in the near future.
    • The faster market growth would be mainly due to growing elderly population and associated diseases, and increasing number of patients with clinical conditions such as sepsis, pneumonia, trauma, pancreatitis, blood transfusions, and smoking habits.

In addition, the global acute respiratory distress syndrome devices market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global acute respiratory distress syndrome market and profiled in this report include Altor BioScience Corporation, Apeptico, Forschung und Entwicklung GmbH, Commence Bio, Inc., CompleGen, Inc., FirstString Research, Inc., GlaxoSmithKline Plc, Histocell S.L., Navigen Pharmaceuticals, Inc., Noxxon Pharma AG, Quark, Pharmaceuticals, Inc., S-Evans Biosciences, Inc., Silence Therapeutics Plc, Stemedica Cell Technologies, Inc. and Windtree Therapeutics, Inc.

  • Product
    • Airway and Pulmonary Management Devices
      • Anesthesia and Respiratory Masks
      • Pulmonary Function Diagnostic Devices
        • Spirometry
        • Others
      • Ventilators
        • Positive Airway Pressure Devices
        • Others
      • Other Devices
    • Drug/Fluid Delivery and Infusion Therapy Devices
      • Inhalation Devices
        • Nebulizers
  • End User
    • Hospitals
    • Clinics
    • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Altor BioScience Corporation
    • Apeptico
    • Forschung und Entwicklung GmbH
    • Commence Bio, Inc.
    • CompleGen, Inc.
    • FirstString Research, Inc.
    • GlaxoSmithKline plc
    • Histocell S.L.
    • Navigen Pharmaceuticals, Inc.
    • Noxxon Pharma AG
    • Quark Pharmaceuticals, Inc.
    • S-Evans Biosciences, Inc.
    • Silence Therapeutics plc
    • Stemedica Cell Technologies, Inc.
    • Windtree Therapeutics, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/acute-respiratory-distress-syndrome-devices-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]